These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4595485)

  • 21. Clinical studies with d-fenfluramine.
    Guy-Grand B
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):173S-176S. PubMed ID: 1728829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of fenfluramine on weight loss during restricted dietary regimes.
    Wales JK
    Int J Obes; 1980; 4(2):127-32. PubMed ID: 7399803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in dietary intake of obese patients treated by diet associated with d-fenfluramine].
    Cairella M; Cairella G; Graziani P; Mirante MG; Taghva AR
    Clin Ter; 1992 Mar; 140(3):235-8. PubMed ID: 1568366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients.
    Kolanowski J; Younis LT; Vanbutsele R; Detry JM
    Eur J Clin Pharmacol; 1992; 42(6):599-605. PubMed ID: 1623900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.
    Engelson ES; Agin D; Kenya S; Werber-Zion G; Luty B; Albu JB; Kotler DP
    Metabolism; 2006 Oct; 55(10):1327-36. PubMed ID: 16979403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronotherapy of obesity. I. Effect of fenfluramine on the decrease of adipose mass in the obese, in relation to the time of administration].
    Guagnano MT; Di Vincenzo M; Sensi S
    Boll Soc Ital Biol Sper; 1982 Jun; 58(12):736-9. PubMed ID: 7104096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity.
    Stunkard AJ; Craighead LW; O'Brien R
    Lancet; 1980 Nov; 2(8203):1045-7. PubMed ID: 6107677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Couples training, pharmacotherapy, and behavior therapy in the treatment of obesity.
    Brownell KD; Stunkard AJ
    Arch Gen Psychiatry; 1981 Nov; 38(11):1224-9. PubMed ID: 7305602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter: Peripheral effects of anorectic drugs.
    Hipkin LJ; Davis JC
    Lancet; 1976 Apr; 1(7962):754. PubMed ID: 56576
    [No Abstract]   [Full Text] [Related]  

  • 35. [Influence of fenfluramine on the weekly curve of weight loss during obesity].
    Cabezas Cerrato J; Gómez Pérez M; Marco-Mur AL; Camarero E; Fernández-Cruz A
    Rev Clin Esp; 1974 Jan; 132(1):47-52. PubMed ID: 4840227
    [No Abstract]   [Full Text] [Related]  

  • 36. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
    Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
    Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of obesity with fenfluramine (Ponderal)].
    Persson I; Andersen UD; Deckert T
    Ugeskr Laeger; 1973 Sep; 135(36):1932-7. PubMed ID: 4590075
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of weight loss during treatment with d-fenfluramine.
    Toornvliet AC; Pijl H; Hopman E; Westendorp RG; Meinders AE
    J Intern Med; 1997 May; 241(5):401-6. PubMed ID: 9183308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of benfluramate on carbohydrate metabolism in obesity.
    Asmal AC; Leary WP; Deppe W; Lockett CJ
    Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):95-103. PubMed ID: 905637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial.
    Ng Tang Fui M; Prendergast LA; Dupuis P; Raval M; Strauss BJ; Zajac JD; Grossmann M
    BMC Med; 2016 Oct; 14(1):153. PubMed ID: 27716209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.